ALDX
Aldeyra Therapeutics, Inc.NASDAQHealthcare$1.66-1.19%ClosedMarket Cap: $99.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.09
P/S
0.00
EV/EBITDA
0.00
DCF Value
$0.91
FCF Yield
30421624.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-63.7%
ROA
-47.0%
ROIC
-59.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-6.7M | $-6.5M | $-0.11 | — |
| FY 2025 | $0.00 | -Infinity% | $-35.3M | $-33.8M | $-0.56 | — |
| Q3 2025 | $0.00 | NaN% | $-8.0M | $-7.7M | $-0.13 | — |
| Q2 2025 | $0.00 | NaN% | $-10.2M | $-9.8M | $-0.16 | — |
| Q1 2025 | $0.00 | NaN% | $-10.4M | $-9.9M | $-0.17 | — |
| Q4 2024 | $0.00 | -Infinity% | $-16.6M | $-15.8M | $-0.27 | — |
| FY 2024 | $0.00 | NaN% | $-60.1M | $-55.9M | $-0.94 | — |
| Q3 2024 | $0.00 | NaN% | $-16.1M | $-15.1M | $-0.25 | — |
| Q2 2024 | $0.00 | NaN% | $-18.0M | $-16.8M | $-0.28 | — |
| Q1 2024 | $0.00 | NaN% | $-9.4M | $-8.1M | $-0.14 | — |
| Q4 2023 | $0.00 | -Infinity% | $-6.1M | $-4.8M | $-0.08 | — |
| FY 2023 | $0.00 | NaN% | $-42.8M | $-37.5M | $-0.64 | — |